多西环素暴露后预防对淋病有效性随时间快速下降
这项回顾性检测阴性观察研究纳入美国南加州Kaiser Permanente医疗系统中26 582名出生时男性且感染HIV或使用HIV暴露前/后预防者,评估多西环素暴露后预防(PEP)对衣原体、淋病和梅毒的真实世界有效性。
要点
- 多西环素PEP对衣原体和梅毒持续有效,但对淋病保护快速丧失。
- 实施多西环素PEP策略时应考虑淋病预防获益有限或短暂。
核心结论
- 多西环素PEP对淋病的有效性在实施后第一年内快速丧失,与淋病奈瑟菌高水平四环素耐药扩张相关。
- 多西环素PEP对衣原体和梅毒在实施两年多后仍保持持续有效性。
- 淋病预防的获益可能有限或短暂,实施策略需考虑抗菌药物耐药扩张的潜在后果。
研究设计与样本
- 回顾性、检测阴性、观察性研究,纳入美国南加州Kaiser Permanente医疗系统中出生时男性且感染HIV或使用HIV暴露前/后预防者。
- 33 118人符合纳入标准,其中26 582人在2023年1月1日至2025年6月30日期间至少接受一次性传播感染检测并纳入主要分析。
- 主要结局为实验室确诊的衣原体、淋病和梅毒感染;采用逻辑回归模型比较检测前90天内多西环素PEP处方配药史与检测结果的关系。
临床怎么用
- 在实施多西环素PEP策略时,应预期其对淋病的保护作用有限或短暂,不应将其作为淋病预防的主要依赖手段。
- 需监测淋病奈瑟菌tetM流行率,以评估多西环素PEP对淋病有效性下降的风险。
- 多西环素PEP对衣原体和梅毒仍可提供持续保护,临床决策应权衡不同感染的获益与耐药风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the USA, post-exposure prophylaxis (PEP) with doxycycline within 72 h after sex is recommended to prevent chlamydia, gonorrhoea, and syphilis in men who have sex with men (MSM) and transgender women. However, concerns surround potential expansion of Neisseria gonorrhoeae lineages harbouring antimicrobial resistance (AMR) in settings that implement doxycycline PEP. We aimed to assess the real-world effectiveness of doxycycline PEP in preventing sexually transmitted infections, and whether effectiveness against N gonorrhoeae infection was durable following doxycycline PEP implementation. METHODS: We conducted a retrospective, test-negative, observational study in individuals receiving care from the Kaiser Permanente Southern California integrated health-care system. Eligible participants were assigned male at birth and living with HIV or receiving HIV pre-exposure prophylaxis or PEP at any time between July 1, 2021, and June 30, 2025. The primary outcomes were laboratory-confirmed chlamydia, gonorrhoea, and syphilis infections in eligible cohort members. Primary analyses used a test-negative design; we fit logistic regression models to estimate protective effectiveness of doxycycline PEP by comparing history of doxycycline PEP prescription fills 90 days or less before positive or negative tests for infection with Chlamydia trachomatis, N gonorrhoeae, and Treponema pallidum. In analyses defining doxycycline PEP effectiveness as a time-varying parameter, we assessed how effectiveness against gonorrhoea infection varied throughout the study period and in association with the proportion of local N gonorrhoeae isolates harbouring tetM, a plasmid-borne gene conferring high-level tetracycline resistance. FINDINGS: 33 118 individuals met eligibility criteria, of whom 26 582 had one or more sexually transmitted infection tests between Jan 1, 2023, and June 30, 2025, and were thus included in the primary analyses. 2262 (8·5%) of 26 582 participants received one or more doxycycline PEP fills. Doxycycline PEP fills occurred 90 days or less before 39 (0·8%) of 4659 positive and 3288 (2·5%) of 130 138 negative C trachomatis tests; 212 (3·%) of 6539 positive and 3112 (2·4%) of 128 238 negative N gonorrhoeae tests; and 11 (0·5%) of 2169 positive and 794 (3·0%) of 26 913 negative T pallidum tests. Throughout the study period, preventive effectiveness of doxycycline PEP against chlamydia was 66·5% (95% CI 53·6 to 75·9), against gonorrhoea was -1·8% (-18·5 to 12·5), and against syphilis was 60·7% (28·3 to 78·5). Effectiveness against gonorrhoea decreased from 42·3% (2·7 to 65·8) before statewide doxycycline PEP implementation to -15·0% (-51·1 to 11·4) between January and June, 2025, in association with a rapid increase of tetM prevalence in circulating N gonorrhoeae lineages. Effectiveness during periods with tetM detected in 20·0-29·9% of N gonorrhoeae isolates was 47·2% (4·1 to 70·3), decreasing to -8·5% (-33·2 to 11·2) during periods with tetM detected in 50% or more of isolates. INTERPRETATION: We report rapid loss of doxycycline PEP effectiveness against gonorrhoea within the first year after doxycycline PEP implementation in MSM and transgender women in southern California, associated with expansion of high-level tetracycline resistance in N gonorrhoeae. Whereas we report sustained doxycycline PEP effectiveness against chlamydia and syphilis more than 2 years after doxycycline PEP implementation, our findings suggest protection against gonorrhoea might not be durable. Risk-benefit considerations for doxycycline PEP implementation strategies should assume limited or transient benefits associated with gonorrhoea prevention, and address potential consequences of AMR expansion in N gonorrhoeae. FUNDING: US Centers for Disease Control and Prevention.
引用
- Yechezkel M, Helekal D, Kapadia B, et al. Durability of doxycycline effectiveness against gonorrhoea after implementation of post-exposure prophylaxis in southern California, USA: a retrospective, test-negative, observational study. Lancet Infect Dis. 2026. PMID: 42107388. doi:10.1016/S1473-3099(26)00123-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。